Guthrie H, Honig LS, Lin H, Sink KM, et al. xSafety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-To-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks. J Alzheimers Dis 2020 Jun 17. pii: JAD200134. doi: 10.3233/JAD-200134.
PMID: 32568196